A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.

Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, Mackenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Weinstein JN, Mills GB, Levine DA, Akbani R (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Book Volume: 33

Pages Range: 690-705.e9

Journal Issue: 4

DOI: 10.1016/j.ccell.2018.03.014

Abstract

We analyzed molecular data on 2,579 tumors from The Cancer Genome Atlas (TCGA) of four gynecological types plus breast. Our aims were to identify shared and unique molecular features, clinically significant subtypes, and potential therapeutic targets. We found 61 somatic copy-number alterations (SCNAs) and 46 significantly mutated genes (SMGs). Eleven SCNAs and 11 SMGs had not been identified in previous TCGA studies of the individual tumor types. We found functionally significant estrogen receptor-regulated long non-coding RNAs (lncRNAs) and gene/lncRNA interaction networks. Pathway analysis identified subtypes with high leukocyte infiltration, raising potential implications for immunotherapy. Using 16 key molecular features, we identified five prognostic subtypes and developed a decision tree that classified patients into the subtypes based on just six features that are assessable in clinical laboratories.

Involved external institutions

Eli and Edythe L. Broad Institute of MIT and Harvard United States (USA) (US) University of Texas MD Anderson Cancer Center United States (USA) (US) Van Andel Institute United States (USA) (US) Houston Texas Medical Center United States (USA) (US) Royal Institute of Technology / Kungliga Tekniska Högskolan (KTH) Sweden (SE) Universiteit Gent (UGent) / Ghent University Belgium (BE) University of Houston United States (USA) (US) Buck Institute for Research on Aging United States (USA) (US) University of São Paulo / Universidade de São Paulo (USP) Brazil (BR) Medical College of Wisconsin (MCW) United States (USA) (US) University of Alabama at Birmingham (UAB) United States (USA) (US) University of New South Wales (UNSW) Australia (AU) Leukemia Therapeutics LLC United States (USA) (US) British Columbia Cancer Agency Canada (CA) Mayo Clinic United States (USA) (US) University of Kansas (KU) United States (USA) (US) University of Oklahoma United States (USA) (US) University of Maryland, College Park (UMD) United States (USA) (US) Wake Forest Baptist Medical Center United States (USA) (US) Cedars-Sinai Medical Center United States (USA) (US) National Cancer Institute (NCI) United States (USA) (US) NYU Langone Medical Center United States (USA) (US)

How to cite

APA:

Berger, A.C., Korkut, A., Kanchi, R.S., Hegde, A.M., Lenoir, W., Liu, W.,... Akbani, R. (2018). A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 33(4), 690-705.e9. https://doi.org/10.1016/j.ccell.2018.03.014

MLA:

Berger, Ashton C., et al. "A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers." Cancer Cell 33.4 (2018): 690-705.e9.

BibTeX: Download